AGIOS PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
AGIO$31.76+1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · Treasury · TotalStockholders’Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| (In thousands, except share amounts) · Shares · Amount · Shares · Amount | ||||||||
| Balance at December 31, 2020 | 69,293,920 | $69 | $2,242,801 | $105 | $(1,843,475) | — | $— | $399,500 |
| Unrealized loss on available-for-sale securities | — | — | — | (1,303) | — | — | — | (1,303) |
| Net income | — | — | — | — | 1,604,715 | — | — | 1,604,715 |
| Stock-based compensation expense | — | — | 53,508 | — | — | — | — | 53,508 |
| Common stock issued under stock incentive plan and ESPP | 1,256,711 | 2 | 37,294 | — | — | — | — | 37,296 |
| Repurchase of common stock | — | — | — | — | — | (16,216,411) | (802,486) | (802,486) |
| Disposition of oncology business | — | — | 745 | — | — | — | — | 745 |
| Balance at December 31, 2021 | 70,550,631 | $71 | $2,334,348 | $(1,198) | $(238,760) | (16,216,411) | $(802,486) | $1,291,975 |
| Unrealized loss on available-for-sale securities | — | — | — | (11,337) | — | — | — | (11,337) |
| Net loss | — | — | — | — | (231,801) | — | — | (231,801) |
| Stock-based compensation expense | — | — | 49,296 | — | — | — | — | 49,296 |
| Common stock issued under stock incentive plan and ESPP | 705,487 | — | 2,681 | — | — | — | — | 2,681 |
| Balance at December 31, 2022 | 71,256,118 | $71 | $2,386,325 | $(12,535) | $(470,561) | (16,216,411) | $(802,486) | $1,100,814 |
| Unrealized gain on available-for-sale securities | — | — | — | 12,094 | — | — | — | 12,094 |
| Net loss | — | — | — | — | (352,088) | — | — | (352,088) |
| Stock-based compensation expense | — | — | 44,766 | — | — | — | — | 44,766 |
| Common stock issued under stock incentive plan and ESPP | 905,371 | 1 | 5,432 | — | — | — | — | 5,433 |
| Balance at December 31, 2023 | 72,161,489 | $72 | $2,436,523 | $(441) | $(822,649) | (16,216,411) | $(802,486) | $811,019 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.